GoldenGolden
Codiak BioSciences

Codiak BioSciences

Codiak Biosciences is a biotechnology company developing exosome therapeutics.

Codiak Biosciences is a biotechnology company developing exosome therapeutics that is headquartered in Cambridge, Massachusetts and was founded by Eric lander and Raghu Kalluri in 2015.

Funding
Series A

On November 17, 2015 Codiak BioSciences completed their series A funding round with $31 million in capital from Flagship Pioneering, ARCH Venture Partners, and Fidelity Management and Research Company.

Series B

On January 26, 2016 Codiak BioSciences completed their series B funding round with $61 million in capital from Flagship Pioneering (lead investor), ARCH Venture Partners (lead investor), Alexandria Venture, and Alaska Permanent Fund.

Series C

On November 27, 2017 Codiak BioSciences completed their series C funding round with $76.5 million in capital from Sirona Capital, Qatar Investment Authority, Flagship Pioneering, Fidelity Management and Research Company.

Timeline

May 20, 2021
Codiak BioSciences appoints Anne-Virginie Eggimann, M.Sc., to its board of directors.
May 10, 2021
Codiak BioSciences Inc. announces the appointment of Jennifer Wheler, M.D. as Chief Medical Officer.

From 2006 to 2015, she worked in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center where she served as Principal Investigator on more than 30 Phase 1 trials, including one of the first published trials of randomized data demonstrating benefit for treating patients with therapy matched to their tumor's molecular profile.

February 2021
Codiak BioSciences raises a $66,400,000 venture round.
November 27, 2017
Series C funding round

On November 27, 2017 Codiak BioSciences completed their series C funding round with $76.5 million in capital from Sirona Capital, Qatar Investment Authority, Flagship Pioneering, Fidelity Management and Research Company.

November 2017
Codiak BioSciences raises a $76,500,000 series C round from ARCH Venture Partners, Alaska Permanent Fund, Boxer Capital, Casdin Capital, EcoR1 Capital, Fidelity Management & Research Company, Flagship Pioneering, Qatar Investment Authority, Sirona Capital and Yukon Partners.
January 26, 2016
Series B funding round

On January 26, 2016 Codiak BioSciences completed their series B funding round with $61 million in capital from Flagship Pioneering (lead investor), ARCH Venture Partners (lead investor), Alexandria Venture, and Alaska Permanent Fund.

January 2016
Codiak BioSciences raises a $61,000,000 series B round from ARCH Venture Partners, Alaska Permanent Fund, Fidelity Management & Research Company, Flagship Pioneering and Yukon Partners.
November 17, 2015
Series A funding round

On November 17, 2015 Codiak BioSciences completed their series A funding round with $31 million in capital from Flagship Pioneering, ARCH Venture Partners, and Fidelity Management and Research Company.

November 2015
Codiak BioSciences raises a $31,000,000 series A round from ARCH Venture Partners, Fidelity Management & Research Company and Flagship Pioneering.
2015
Codiak BioSciences was founded by Eric Lander and Raghu Kalluri.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Codiak BioSciences Presents First Data on exoSTING - A Novel Engineered Exosome Therapeutic Targeting Checkpoint Refractory Tumors at the Society for Immunotherapy of Cancer's 33rd Annual Meeting

Codiak BioSciences, Inc.

Web

What You Need to Know About Codiak BioSciences

Mark Terry

Web

Xconomy: VCs Put More Dollars Into Exosomes as Codiak Bio Lands $76M

Ben Fidler

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 15, 2021
BioSpace
Codiak BioSciences, Inc. today announced the promotion of Sriram Sathyanarayanan, Ph.D.
BioSpace
May 20, 2021
BioSpace
Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has appointed Anne-Virginie Eggimann, M.Sc., to its board of directors.
Alex Keown
May 14, 2021
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.
BioSpace
May 11, 2021
BioSpace
Data at ASGCT 2021 show ability to design exosomes with specific features for immune evasion, tunable vaccine development, targeted cell tropism and potent target engagement
BioSpace
May 10, 2021
BioSpace
Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the appointment of Jennifer Wheler, M.D.
BioSpace
April 27, 2021
BioSpace
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced that the company will present data from its engExTM Platform at the 24th Annual Meeting of the American Society of Gene and Cell Therapy, which is being held virtually from May 11-14, 2021.
BioSpace
April 22, 2021
BioSpace
Codiak BioSciences, Inc., a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced the online publication of a new manuscript, exoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance, in Communications Biology, a Nature Research publication.
BioSpace
April 22, 2021
BioSpace
Codiak BioSciences, Inc., a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced the online publication of a new manuscript, exoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance, in Communications Biology, a Nature Research publication.
BioSpace
November 9, 2020
BioSpace
Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that preclinical data from programs using its engExTM Platform are being presented this week at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Amirah Al Idrus
June 23, 2020
FierceBiotech
Sarepta is on the hunt for new ways to deliver genetic medicines. Its latest target? A system the body's cells use to communicate with each other. The company is teaming up with Codiak Biosciences to develop engineered exosomes that can deliver gene therapy, gene editing or RNA-based treatments.
BioSpace Editorial Staff
June 1, 2020
BioSpace
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.